The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the ...

A woman's chances of surviving ovarian cancer at least five years after diagnosis come down to the toss of a coin: just 49% ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

STAAR Low-Grade Serous Ovarian Cancer Foundation and Not These Ovaries Fund Breakthrough Research at MD Anderson Cancer ...

The FDA has granted accelerated approval to the combination therapy of avutometinib and defactinib (Avmapki Fakzynja Co-pack) ...

A promising target for rare liver cancer, a functional cure for multiple myeloma — and support for people with ovarian cancer.

Initial results from the LANCE trial show comparable rates of resection with minimally invasive surgery and laparotomy in ...

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...

World Ovarian Cancer Day, observed on May 8, raises awareness, promotes early diagnosis, and calls for global action to ...

In 2023, the Rivkin Center partnered with the Andy Hill Cancer Research ... is optimizing a novel delivery system for an ovarian cancer vaccine. The treatment aims to prevent the spread of ...

Exercise can mitigate some of the side effects of cancer treatments across a range of cancer types, according to a recent ...